Global Enoxaparin Market

Enoxaparin Comprehensive Study by Application (Infectious Diseases, Gynecology, Cancer, Diabetes, Cardiology, Osteoporosis, Others), Age Group (Adults, Children (2 months to 18 yr), Infants (1 to 2 months)), End User (Hospitals, Clinics, Research Institutes, Others) Players and Region - Global Market Outlook to 2026

Enoxaparin Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Enoxaparin Market Overview:
Enoxaparin is a low molecular weight heparin, which is used to avoid deep venous thrombosis, harmful blood clots form in the blood vessels of the human’s legs. Blood clots can travel through the lungs and can become stuck in the blood vessels of the lungs, causing a condition called pulmonary embolism. This drug is used for several days after knee or hip replacement surgery, and in some cases of abdominal surgery and also in a serious illness. Moreover, enoxaparin is used to prevent blood clots from forming in the arteries of the heart during heart attacks and chest pain. These applications of the Enoxaparin are propelling the growth of the Enoxaparin market.

Growth Drivers
  • Increasing Prevalence of Chronic Diseases like Diabetes, Cancer, and Osteoporosis
  • Increasing Healthcare Industry Globally

Roadblocks
  • Availability of Alternative Drugs for Enoxaparin

Opportunities
  • Government’s Initiative to Support Pharmaceutical Companies


Competitive Landscape:

Some of the key players profiled in the report are Teva Pharmaceutical Industries Ltd. (Israel), GlaxoSmithKline Plc. (United Kingdom), Mitsubishi Tanabe Pharma Corporation (Japan), Bayer Healthcare AG (Germany), Aspen Holdings (South Africa), Eisai Inc. (United States), Pfizer, Inc. (United States), Boehringer Ingelheim (Germany), Abbott India Limited (India) and Bristol-Myers Squibb Company (United States). Additionally, following companies can also be profiled that are part of our coverage like Sanofi S.A. (France). Analyst at AMA Research see European Players to retain maximum share of Global Enoxaparin market by 2026. Considering Market by Age Group, the sub-segment i.e. Adults will boost the Enoxaparin market. Considering Market by End User, the sub-segment i.e. Hospitals will boost the Enoxaparin market.

What Can be Explored with the Enoxaparin Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Enoxaparin Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Enoxaparin
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Enoxaparin market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Enoxaparin market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Enoxaparin Manufacturers, Potential Technology Investors, Regulatory & Government Bodies, Downstream Vendors, End Users and Other.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Application
  • Infectious Diseases
  • Gynecology
  • Cancer
  • Diabetes
  • Cardiology
  • Osteoporosis
  • Others
By Age Group
  • Adults
  • Children (2 months to 18 yr)
  • Infants (1 to 2 months)

By End User
  • Hospitals
  • Clinics
  • Research Institutes
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Prevalence of Chronic Diseases like Diabetes, Cancer, and Osteoporosis
      • 3.2.2. Increasing Healthcare Industry Globally
    • 3.3. Market Trends
      • 3.3.1. Increasing Healthcare Expenditure in Emerging Economies
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Enoxaparin, by Application, Age Group, End User and Region (value and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Enoxaparin (Value)
      • 5.2.1. Global Enoxaparin by: Application (Value)
        • 5.2.1.1. Infectious Diseases
        • 5.2.1.2. Gynecology
        • 5.2.1.3. Cancer
        • 5.2.1.4. Diabetes
        • 5.2.1.5. Cardiology
        • 5.2.1.6. Osteoporosis
        • 5.2.1.7. Others
      • 5.2.2. Global Enoxaparin by: Age Group (Value)
        • 5.2.2.1. Adults
        • 5.2.2.2. Children (2 months to 18 yr)
        • 5.2.2.3. Infants (1 to 2 months)
      • 5.2.3. Global Enoxaparin by: End User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Clinics
        • 5.2.3.3. Research Institutes
        • 5.2.3.4. Others
      • 5.2.4. Global Enoxaparin Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Enoxaparin (Price)
  • 6. Enoxaparin: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Teva Pharmaceutical Industries Ltd. (Israel)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. GlaxoSmithKline Plc. (United Kingdom)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Mitsubishi Tanabe Pharma Corporation (Japan)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bayer Healthcare AG (Germany)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Aspen Holdings (South Africa)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Eisai Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Pfizer, Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Boehringer Ingelheim (Germany)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Abbott India Limited (India)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Bristol-Myers Squibb Company (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Enoxaparin Sale, by Application, Age Group, End User and Region (value and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Enoxaparin (Value)
      • 7.2.1. Global Enoxaparin by: Application (Value)
        • 7.2.1.1. Infectious Diseases
        • 7.2.1.2. Gynecology
        • 7.2.1.3. Cancer
        • 7.2.1.4. Diabetes
        • 7.2.1.5. Cardiology
        • 7.2.1.6. Osteoporosis
        • 7.2.1.7. Others
      • 7.2.2. Global Enoxaparin by: Age Group (Value)
        • 7.2.2.1. Adults
        • 7.2.2.2. Children (2 months to 18 yr)
        • 7.2.2.3. Infants (1 to 2 months)
      • 7.2.3. Global Enoxaparin by: End User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Clinics
        • 7.2.3.3. Research Institutes
        • 7.2.3.4. Others
      • 7.2.4. Global Enoxaparin Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Enoxaparin (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Enoxaparin: by Application(USD Million)
  • Table 2. Enoxaparin Infectious Diseases , by Region USD Million (2015-2020)
  • Table 3. Enoxaparin Gynecology , by Region USD Million (2015-2020)
  • Table 4. Enoxaparin Cancer , by Region USD Million (2015-2020)
  • Table 5. Enoxaparin Diabetes , by Region USD Million (2015-2020)
  • Table 6. Enoxaparin Cardiology , by Region USD Million (2015-2020)
  • Table 7. Enoxaparin Osteoporosis , by Region USD Million (2015-2020)
  • Table 8. Enoxaparin Others , by Region USD Million (2015-2020)
  • Table 9. Enoxaparin: by Age Group(USD Million)
  • Table 10. Enoxaparin Adults , by Region USD Million (2015-2020)
  • Table 11. Enoxaparin Children (2 months to 18 yr) , by Region USD Million (2015-2020)
  • Table 12. Enoxaparin Infants (1 to 2 months) , by Region USD Million (2015-2020)
  • Table 13. Enoxaparin: by End User(USD Million)
  • Table 14. Enoxaparin Hospitals , by Region USD Million (2015-2020)
  • Table 15. Enoxaparin Clinics , by Region USD Million (2015-2020)
  • Table 16. Enoxaparin Research Institutes , by Region USD Million (2015-2020)
  • Table 17. Enoxaparin Others , by Region USD Million (2015-2020)
  • Table 18. South America Enoxaparin, by Country USD Million (2015-2020)
  • Table 19. South America Enoxaparin, by Application USD Million (2015-2020)
  • Table 20. South America Enoxaparin, by Age Group USD Million (2015-2020)
  • Table 21. South America Enoxaparin, by End User USD Million (2015-2020)
  • Table 22. Brazil Enoxaparin, by Application USD Million (2015-2020)
  • Table 23. Brazil Enoxaparin, by Age Group USD Million (2015-2020)
  • Table 24. Brazil Enoxaparin, by End User USD Million (2015-2020)
  • Table 25. Argentina Enoxaparin, by Application USD Million (2015-2020)
  • Table 26. Argentina Enoxaparin, by Age Group USD Million (2015-2020)
  • Table 27. Argentina Enoxaparin, by End User USD Million (2015-2020)
  • Table 28. Rest of South America Enoxaparin, by Application USD Million (2015-2020)
  • Table 29. Rest of South America Enoxaparin, by Age Group USD Million (2015-2020)
  • Table 30. Rest of South America Enoxaparin, by End User USD Million (2015-2020)
  • Table 31. Asia Pacific Enoxaparin, by Country USD Million (2015-2020)
  • Table 32. Asia Pacific Enoxaparin, by Application USD Million (2015-2020)
  • Table 33. Asia Pacific Enoxaparin, by Age Group USD Million (2015-2020)
  • Table 34. Asia Pacific Enoxaparin, by End User USD Million (2015-2020)
  • Table 35. China Enoxaparin, by Application USD Million (2015-2020)
  • Table 36. China Enoxaparin, by Age Group USD Million (2015-2020)
  • Table 37. China Enoxaparin, by End User USD Million (2015-2020)
  • Table 38. Japan Enoxaparin, by Application USD Million (2015-2020)
  • Table 39. Japan Enoxaparin, by Age Group USD Million (2015-2020)
  • Table 40. Japan Enoxaparin, by End User USD Million (2015-2020)
  • Table 41. India Enoxaparin, by Application USD Million (2015-2020)
  • Table 42. India Enoxaparin, by Age Group USD Million (2015-2020)
  • Table 43. India Enoxaparin, by End User USD Million (2015-2020)
  • Table 44. South Korea Enoxaparin, by Application USD Million (2015-2020)
  • Table 45. South Korea Enoxaparin, by Age Group USD Million (2015-2020)
  • Table 46. South Korea Enoxaparin, by End User USD Million (2015-2020)
  • Table 47. Taiwan Enoxaparin, by Application USD Million (2015-2020)
  • Table 48. Taiwan Enoxaparin, by Age Group USD Million (2015-2020)
  • Table 49. Taiwan Enoxaparin, by End User USD Million (2015-2020)
  • Table 50. Australia Enoxaparin, by Application USD Million (2015-2020)
  • Table 51. Australia Enoxaparin, by Age Group USD Million (2015-2020)
  • Table 52. Australia Enoxaparin, by End User USD Million (2015-2020)
  • Table 53. Rest of Asia-Pacific Enoxaparin, by Application USD Million (2015-2020)
  • Table 54. Rest of Asia-Pacific Enoxaparin, by Age Group USD Million (2015-2020)
  • Table 55. Rest of Asia-Pacific Enoxaparin, by End User USD Million (2015-2020)
  • Table 56. Europe Enoxaparin, by Country USD Million (2015-2020)
  • Table 57. Europe Enoxaparin, by Application USD Million (2015-2020)
  • Table 58. Europe Enoxaparin, by Age Group USD Million (2015-2020)
  • Table 59. Europe Enoxaparin, by End User USD Million (2015-2020)
  • Table 60. Germany Enoxaparin, by Application USD Million (2015-2020)
  • Table 61. Germany Enoxaparin, by Age Group USD Million (2015-2020)
  • Table 62. Germany Enoxaparin, by End User USD Million (2015-2020)
  • Table 63. France Enoxaparin, by Application USD Million (2015-2020)
  • Table 64. France Enoxaparin, by Age Group USD Million (2015-2020)
  • Table 65. France Enoxaparin, by End User USD Million (2015-2020)
  • Table 66. Italy Enoxaparin, by Application USD Million (2015-2020)
  • Table 67. Italy Enoxaparin, by Age Group USD Million (2015-2020)
  • Table 68. Italy Enoxaparin, by End User USD Million (2015-2020)
  • Table 69. United Kingdom Enoxaparin, by Application USD Million (2015-2020)
  • Table 70. United Kingdom Enoxaparin, by Age Group USD Million (2015-2020)
  • Table 71. United Kingdom Enoxaparin, by End User USD Million (2015-2020)
  • Table 72. Netherlands Enoxaparin, by Application USD Million (2015-2020)
  • Table 73. Netherlands Enoxaparin, by Age Group USD Million (2015-2020)
  • Table 74. Netherlands Enoxaparin, by End User USD Million (2015-2020)
  • Table 75. Rest of Europe Enoxaparin, by Application USD Million (2015-2020)
  • Table 76. Rest of Europe Enoxaparin, by Age Group USD Million (2015-2020)
  • Table 77. Rest of Europe Enoxaparin, by End User USD Million (2015-2020)
  • Table 78. MEA Enoxaparin, by Country USD Million (2015-2020)
  • Table 79. MEA Enoxaparin, by Application USD Million (2015-2020)
  • Table 80. MEA Enoxaparin, by Age Group USD Million (2015-2020)
  • Table 81. MEA Enoxaparin, by End User USD Million (2015-2020)
  • Table 82. Middle East Enoxaparin, by Application USD Million (2015-2020)
  • Table 83. Middle East Enoxaparin, by Age Group USD Million (2015-2020)
  • Table 84. Middle East Enoxaparin, by End User USD Million (2015-2020)
  • Table 85. Africa Enoxaparin, by Application USD Million (2015-2020)
  • Table 86. Africa Enoxaparin, by Age Group USD Million (2015-2020)
  • Table 87. Africa Enoxaparin, by End User USD Million (2015-2020)
  • Table 88. North America Enoxaparin, by Country USD Million (2015-2020)
  • Table 89. North America Enoxaparin, by Application USD Million (2015-2020)
  • Table 90. North America Enoxaparin, by Age Group USD Million (2015-2020)
  • Table 91. North America Enoxaparin, by End User USD Million (2015-2020)
  • Table 92. United States Enoxaparin, by Application USD Million (2015-2020)
  • Table 93. United States Enoxaparin, by Age Group USD Million (2015-2020)
  • Table 94. United States Enoxaparin, by End User USD Million (2015-2020)
  • Table 95. Canada Enoxaparin, by Application USD Million (2015-2020)
  • Table 96. Canada Enoxaparin, by Age Group USD Million (2015-2020)
  • Table 97. Canada Enoxaparin, by End User USD Million (2015-2020)
  • Table 98. Mexico Enoxaparin, by Application USD Million (2015-2020)
  • Table 99. Mexico Enoxaparin, by Age Group USD Million (2015-2020)
  • Table 100. Mexico Enoxaparin, by End User USD Million (2015-2020)
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Enoxaparin: by Application(USD Million)
  • Table 112. Enoxaparin Infectious Diseases , by Region USD Million (2021-2026)
  • Table 113. Enoxaparin Gynecology , by Region USD Million (2021-2026)
  • Table 114. Enoxaparin Cancer , by Region USD Million (2021-2026)
  • Table 115. Enoxaparin Diabetes , by Region USD Million (2021-2026)
  • Table 116. Enoxaparin Cardiology , by Region USD Million (2021-2026)
  • Table 117. Enoxaparin Osteoporosis , by Region USD Million (2021-2026)
  • Table 118. Enoxaparin Others , by Region USD Million (2021-2026)
  • Table 119. Enoxaparin: by Age Group(USD Million)
  • Table 120. Enoxaparin Adults , by Region USD Million (2021-2026)
  • Table 121. Enoxaparin Children (2 months to 18 yr) , by Region USD Million (2021-2026)
  • Table 122. Enoxaparin Infants (1 to 2 months) , by Region USD Million (2021-2026)
  • Table 123. Enoxaparin: by End User(USD Million)
  • Table 124. Enoxaparin Hospitals , by Region USD Million (2021-2026)
  • Table 125. Enoxaparin Clinics , by Region USD Million (2021-2026)
  • Table 126. Enoxaparin Research Institutes , by Region USD Million (2021-2026)
  • Table 127. Enoxaparin Others , by Region USD Million (2021-2026)
  • Table 128. South America Enoxaparin, by Country USD Million (2021-2026)
  • Table 129. South America Enoxaparin, by Application USD Million (2021-2026)
  • Table 130. South America Enoxaparin, by Age Group USD Million (2021-2026)
  • Table 131. South America Enoxaparin, by End User USD Million (2021-2026)
  • Table 132. Brazil Enoxaparin, by Application USD Million (2021-2026)
  • Table 133. Brazil Enoxaparin, by Age Group USD Million (2021-2026)
  • Table 134. Brazil Enoxaparin, by End User USD Million (2021-2026)
  • Table 135. Argentina Enoxaparin, by Application USD Million (2021-2026)
  • Table 136. Argentina Enoxaparin, by Age Group USD Million (2021-2026)
  • Table 137. Argentina Enoxaparin, by End User USD Million (2021-2026)
  • Table 138. Rest of South America Enoxaparin, by Application USD Million (2021-2026)
  • Table 139. Rest of South America Enoxaparin, by Age Group USD Million (2021-2026)
  • Table 140. Rest of South America Enoxaparin, by End User USD Million (2021-2026)
  • Table 141. Asia Pacific Enoxaparin, by Country USD Million (2021-2026)
  • Table 142. Asia Pacific Enoxaparin, by Application USD Million (2021-2026)
  • Table 143. Asia Pacific Enoxaparin, by Age Group USD Million (2021-2026)
  • Table 144. Asia Pacific Enoxaparin, by End User USD Million (2021-2026)
  • Table 145. China Enoxaparin, by Application USD Million (2021-2026)
  • Table 146. China Enoxaparin, by Age Group USD Million (2021-2026)
  • Table 147. China Enoxaparin, by End User USD Million (2021-2026)
  • Table 148. Japan Enoxaparin, by Application USD Million (2021-2026)
  • Table 149. Japan Enoxaparin, by Age Group USD Million (2021-2026)
  • Table 150. Japan Enoxaparin, by End User USD Million (2021-2026)
  • Table 151. India Enoxaparin, by Application USD Million (2021-2026)
  • Table 152. India Enoxaparin, by Age Group USD Million (2021-2026)
  • Table 153. India Enoxaparin, by End User USD Million (2021-2026)
  • Table 154. South Korea Enoxaparin, by Application USD Million (2021-2026)
  • Table 155. South Korea Enoxaparin, by Age Group USD Million (2021-2026)
  • Table 156. South Korea Enoxaparin, by End User USD Million (2021-2026)
  • Table 157. Taiwan Enoxaparin, by Application USD Million (2021-2026)
  • Table 158. Taiwan Enoxaparin, by Age Group USD Million (2021-2026)
  • Table 159. Taiwan Enoxaparin, by End User USD Million (2021-2026)
  • Table 160. Australia Enoxaparin, by Application USD Million (2021-2026)
  • Table 161. Australia Enoxaparin, by Age Group USD Million (2021-2026)
  • Table 162. Australia Enoxaparin, by End User USD Million (2021-2026)
  • Table 163. Rest of Asia-Pacific Enoxaparin, by Application USD Million (2021-2026)
  • Table 164. Rest of Asia-Pacific Enoxaparin, by Age Group USD Million (2021-2026)
  • Table 165. Rest of Asia-Pacific Enoxaparin, by End User USD Million (2021-2026)
  • Table 166. Europe Enoxaparin, by Country USD Million (2021-2026)
  • Table 167. Europe Enoxaparin, by Application USD Million (2021-2026)
  • Table 168. Europe Enoxaparin, by Age Group USD Million (2021-2026)
  • Table 169. Europe Enoxaparin, by End User USD Million (2021-2026)
  • Table 170. Germany Enoxaparin, by Application USD Million (2021-2026)
  • Table 171. Germany Enoxaparin, by Age Group USD Million (2021-2026)
  • Table 172. Germany Enoxaparin, by End User USD Million (2021-2026)
  • Table 173. France Enoxaparin, by Application USD Million (2021-2026)
  • Table 174. France Enoxaparin, by Age Group USD Million (2021-2026)
  • Table 175. France Enoxaparin, by End User USD Million (2021-2026)
  • Table 176. Italy Enoxaparin, by Application USD Million (2021-2026)
  • Table 177. Italy Enoxaparin, by Age Group USD Million (2021-2026)
  • Table 178. Italy Enoxaparin, by End User USD Million (2021-2026)
  • Table 179. United Kingdom Enoxaparin, by Application USD Million (2021-2026)
  • Table 180. United Kingdom Enoxaparin, by Age Group USD Million (2021-2026)
  • Table 181. United Kingdom Enoxaparin, by End User USD Million (2021-2026)
  • Table 182. Netherlands Enoxaparin, by Application USD Million (2021-2026)
  • Table 183. Netherlands Enoxaparin, by Age Group USD Million (2021-2026)
  • Table 184. Netherlands Enoxaparin, by End User USD Million (2021-2026)
  • Table 185. Rest of Europe Enoxaparin, by Application USD Million (2021-2026)
  • Table 186. Rest of Europe Enoxaparin, by Age Group USD Million (2021-2026)
  • Table 187. Rest of Europe Enoxaparin, by End User USD Million (2021-2026)
  • Table 188. MEA Enoxaparin, by Country USD Million (2021-2026)
  • Table 189. MEA Enoxaparin, by Application USD Million (2021-2026)
  • Table 190. MEA Enoxaparin, by Age Group USD Million (2021-2026)
  • Table 191. MEA Enoxaparin, by End User USD Million (2021-2026)
  • Table 192. Middle East Enoxaparin, by Application USD Million (2021-2026)
  • Table 193. Middle East Enoxaparin, by Age Group USD Million (2021-2026)
  • Table 194. Middle East Enoxaparin, by End User USD Million (2021-2026)
  • Table 195. Africa Enoxaparin, by Application USD Million (2021-2026)
  • Table 196. Africa Enoxaparin, by Age Group USD Million (2021-2026)
  • Table 197. Africa Enoxaparin, by End User USD Million (2021-2026)
  • Table 198. North America Enoxaparin, by Country USD Million (2021-2026)
  • Table 199. North America Enoxaparin, by Application USD Million (2021-2026)
  • Table 200. North America Enoxaparin, by Age Group USD Million (2021-2026)
  • Table 201. North America Enoxaparin, by End User USD Million (2021-2026)
  • Table 202. United States Enoxaparin, by Application USD Million (2021-2026)
  • Table 203. United States Enoxaparin, by Age Group USD Million (2021-2026)
  • Table 204. United States Enoxaparin, by End User USD Million (2021-2026)
  • Table 205. Canada Enoxaparin, by Application USD Million (2021-2026)
  • Table 206. Canada Enoxaparin, by Age Group USD Million (2021-2026)
  • Table 207. Canada Enoxaparin, by End User USD Million (2021-2026)
  • Table 208. Mexico Enoxaparin, by Application USD Million (2021-2026)
  • Table 209. Mexico Enoxaparin, by Age Group USD Million (2021-2026)
  • Table 210. Mexico Enoxaparin, by End User USD Million (2021-2026)
  • Table 211. Research Programs/Design for This Report
  • Table 212. Key Data Information from Secondary Sources
  • Table 213. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Enoxaparin: by Application USD Million (2015-2020)
  • Figure 5. Global Enoxaparin: by Age Group USD Million (2015-2020)
  • Figure 6. Global Enoxaparin: by End User USD Million (2015-2020)
  • Figure 7. South America Enoxaparin Share (%), by Country
  • Figure 8. Asia Pacific Enoxaparin Share (%), by Country
  • Figure 9. Europe Enoxaparin Share (%), by Country
  • Figure 10. MEA Enoxaparin Share (%), by Country
  • Figure 11. North America Enoxaparin Share (%), by Country
  • Figure 12. Global Enoxaparin share by Players 2020 (%)
  • Figure 13. Global Enoxaparin share by Players (Top 3) 2020(%)
  • Figure 14. Global Enoxaparin share by Players (Top 5) 2020(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Teva Pharmaceutical Industries Ltd. (Israel) Revenue, Net Income and Gross profit
  • Figure 17. Teva Pharmaceutical Industries Ltd. (Israel) Revenue: by Geography 2020
  • Figure 18. GlaxoSmithKline Plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 19. GlaxoSmithKline Plc. (United Kingdom) Revenue: by Geography 2020
  • Figure 20. Mitsubishi Tanabe Pharma Corporation (Japan) Revenue, Net Income and Gross profit
  • Figure 21. Mitsubishi Tanabe Pharma Corporation (Japan) Revenue: by Geography 2020
  • Figure 22. Bayer Healthcare AG (Germany) Revenue, Net Income and Gross profit
  • Figure 23. Bayer Healthcare AG (Germany) Revenue: by Geography 2020
  • Figure 24. Aspen Holdings (South Africa) Revenue, Net Income and Gross profit
  • Figure 25. Aspen Holdings (South Africa) Revenue: by Geography 2020
  • Figure 26. Eisai Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 27. Eisai Inc. (United States) Revenue: by Geography 2020
  • Figure 28. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 29. Pfizer, Inc. (United States) Revenue: by Geography 2020
  • Figure 30. Boehringer Ingelheim (Germany) Revenue, Net Income and Gross profit
  • Figure 31. Boehringer Ingelheim (Germany) Revenue: by Geography 2020
  • Figure 32. Abbott India Limited (India) Revenue, Net Income and Gross profit
  • Figure 33. Abbott India Limited (India) Revenue: by Geography 2020
  • Figure 34. Bristol-Myers Squibb Company (United States) Revenue, Net Income and Gross profit
  • Figure 35. Bristol-Myers Squibb Company (United States) Revenue: by Geography 2020
  • Figure 36. Global Enoxaparin: by Application USD Million (2021-2026)
  • Figure 37. Global Enoxaparin: by Age Group USD Million (2021-2026)
  • Figure 38. Global Enoxaparin: by End User USD Million (2021-2026)
  • Figure 39. South America Enoxaparin Share (%), by Country
  • Figure 40. Asia Pacific Enoxaparin Share (%), by Country
  • Figure 41. Europe Enoxaparin Share (%), by Country
  • Figure 42. MEA Enoxaparin Share (%), by Country
  • Figure 43. North America Enoxaparin Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Teva Pharmaceutical Industries Ltd. (Israel)
  • GlaxoSmithKline Plc. (United Kingdom)
  • Mitsubishi Tanabe Pharma Corporation (Japan)
  • Bayer Healthcare AG (Germany)
  • Aspen Holdings (South Africa)
  • Eisai Inc. (United States)
  • Pfizer, Inc. (United States)
  • Boehringer Ingelheim (Germany)
  • Abbott India Limited (India)
  • Bristol-Myers Squibb Company (United States)
Additional players considered in the study are as follows:
Sanofi S.A. (France)
Select User Access Type

Key Highlights of Report


Dec 2021 219 Pages 85 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Enoxaparin Market Quantitative research analysis
Global Enoxaparin Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The Enoxaparin market is expected to see a CAGR of % during projected year 2020 to 2026.
Top performing companies in the Global Enoxaparin market are Teva Pharmaceutical Industries Ltd. (Israel), GlaxoSmithKline Plc. (United Kingdom), Mitsubishi Tanabe Pharma Corporation (Japan), Bayer Healthcare AG (Germany), Aspen Holdings (South Africa), Eisai Inc. (United States), Pfizer, Inc. (United States), Boehringer Ingelheim (Germany), Abbott India Limited (India) and Bristol-Myers Squibb Company (United States), to name a few.
"Increasing Healthcare Expenditure in Emerging Economies" is seen as one of major influencing trends for Enoxaparin Market during projected period 2020-2026.

Know More About Global Enoxaparin Market Report?

Have a Query? Click Here

Other Related Reports

Famotidine Injection Comprehensive Study by Type (Premixed Solution, Concentrated Solution), Application (Ulcers, Gastroesophageal Reflux Disease, Zollinger-Ellison Syndrome, Others), Components (L-a...
$ 3750
Dog and Cat Calcium Tablet Comprehensive Study by Type (Plant Source, Systhesis), Application (Dogs, Cats), Distribution Channel (Online, Offline, Special Store, Others), Ingredients (Calcium, Vitami...
$ 3800
Finasteride Tablet Comprehensive Study by Type (1mg Tablet, 5mg Tablet), Application (Male Pattern Baldness, Benign Prostatic Hyperplasia, Others) Players and Region - Global Market Outlook to 2025
$ 3500
Dog Vaccine Comprehensive Study by Type (Attenuated Live Vaccines, Inactivated Vaccines, Toxoid Vaccines, Recombinant Vaccines, Therapeutic Biologics, Others), Vaccine Consumption (Less than 6 Months...
$ 3650
Eyedrops Comprehensive Study by Type (Artificial tears, Allergy drops, Anti-redness drops), Application (Glaucoma, Eye Infections, Allergies, Dry Eyes, Others), Nature (Natural, Homeopathic, Herbal),...
$ 3650
Isosorbide Mononitrate Comprehensive Study by Type (10 mg Tablet, 20 mg Tablet), Application (Angina Pectoris, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies...
$ 3500